An innovative new treatment option for bladder cancer, recently approved by the U.S. Food and Drug Administration, has been performed for the first time in Maryland.
The addition of durvalumab to bacillus Calmette-Guérin therapy significantly extended DFS for patients with high-risk non-muscle-invasive bladder cancer, according to results of a randomized phase 3 ...
On Sept. 5, 2025, the U.S. Food and Drug Administration (FDA) approved Inlexzo (gemcitabine intravesical system) for adults ...
Circulating tumour DNA-guided adjuvant atezolizumab prolongs disease-free and overall survival in patients with ...
The "Bladder Cancer Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.The market's growth is primarily driven by the rising ...
Education and public awareness are crucial for patients navigating BCG-unresponsive non-muscle invasive bladder cancer treatment options.
Learn the symptoms of bladder cancer —blood in the urine, pain, and irritation or obstruction when urinating —and when to see a healthcare provider.
The "Non Muscle Invasive Bladder Cancer - Pipeline Insight, 2025" report highlights significant R&D opportunities with over 20 companies and 22 pipeline drugs, focusing on innovative treatments like ...
From intensifying therapy in ctDNA-positive bladder cancer to scaling it back in ctDNA-negative colon cancer, new data from ...
Researchers at UW’s School of Medicine and the Institute for Research in Biomedicine Barcelona may have found an additional explanation as to why men and smokers are more likely to develop bladder ...
Medpage Today on MSN
First-Line Bladder Cancer Trial Makes the Case for HER2 Screening
The first iteration of HER2-targeted drugs showed limited activity in bladder cancer, but the rise of antibody-drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback